Bob Irving
CEO
Biodetectors Pty Ltd
Australia
Biography
Following a PhD in the molecular biology study of prostate cancer in London at the Imperial Cancer Research Fund (1977), Bob spent 10 years in Canada at the National and Alberta Research Councils researching animal viruses, breast cancer molecular biology, plant engineering and engineering microorganisms for biomass to biofuel conversions. Research in Australia at CSIRO for understanding designing and developing recombinant antibodies for therapeutic and diagnostic reagent applications and device design and production; followed by application of bionanotechnology innovations to diagnostic and therapeutic system improvements, and commercialisation. Working with human health providers, government, commercial and research organisations spanning Indonesia, Malaysia, UK, Thailand, Taiwan, Europe including Italy, USA and Chile. Evolved spinout companies from CSIRO including EvoGenix Pty Ltd and its subsequent embodiments. As commercial and scientific director of Nanotechnology Victoria, identified, developed and commercialised the nanotechnology research from stakeholder universities; a key focus being medical nanotechnology for inexpensive and community/personal use diagnostic devices. In 2009 start-up CEO for Bioectors Pty Ltd., after establishing Quintain Consulting Pty Ltd (QC) for diagnostic and bionanotechnology services covering research, evaluation and management including the application of nanotechnology for improved testing and diagnostic performance and most recently for the conversion of biomass to bioenergy (biofuel). Also advises on commercialisation strategies, techno economic assessments and deal-making to local, federal and overseas governments, universities and companies.
Research Interest
Bionanotechnology for drug delivery, improved therapeutic drugs and development of improved delivery methods expanding to diagnostics and diagnostic devices for nanomedicine.